RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES

Authors :: Maurizio Mascarin
Laurence Brugières
Stephen Francis
Alberto Garaventa
Thomas Manley
Salvatore Buffardi
Mariana Sacchi
C Mauz-Körholz
Paul Harker-Murray
Thierry Leblanc
Auke Beishuizen
Stacy Cooper
Richard A. Drachtman
Stephen Daw
Gérard Michel
Kasey J. Leger
Kara M. Kelly
Peter D. Cole
Source :: Hematological Oncology. 37:56-57
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Checkmate
Hematology
General Medicine
Internal medicine
Relapsed refractory
Classical Hodgkin lymphoma
Medicine
Nivolumab
business
Brentuximab vedotin
medicine.drug

Full Text Access

Tools